Published in Pharma Investments, Ventures and Law Weekly, July 11th, 2004
The amended plan will be subject to shareholder approval at Biovail's annual and special meeting on June 25, 2004.
Under the terms of the amended plan, the maximum number of common shares issuable pursuant to the exercise of options will be reduced from 10 million to 5 million. Further, the maximum number of common shares issuable pursuant to options to non-employee directors, together with the number of common shares issuable to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.